Baidu
map

Cell:大脑如何“学习”可卡因成瘾

2013-08-05 koo bio360

日前,约翰霍普金斯大学医学院等机构的研究人员解决了一个长期困扰科学界的问题,他们揭示了在可卡因成瘾过程中,学习相关蛋白如何与其他蛋白相互作用进而激活"快乐分子"多巴胺的作用机制。相关研究论文刊登在了近期出版的《细胞》(Cell)杂志上。 该论文的主要作者、约翰霍普金斯大学医学院神经生物学系教授 Paul Worley 表示,可卡因如何增强大脑特异环路,让大脑对其产生依赖,这是一个很棘手的问题

日前,约翰霍普金斯大学医学院等机构的研究人员解决了一个长期困扰科学界的问题,他们揭示了在可卡因成瘾过程中,学习相关蛋白如何与其他蛋白相互作用进而激活"快乐分子"多巴胺的作用机制。相关研究论文刊登在了近期出版的《细胞》(Cell)杂志上。

该论文的主要作者、约翰霍普金斯大学医学院神经生物学系教授 Paul Worley 表示,可卡因如何增强大脑特异环路,让大脑对其产生依赖,这是一个很棘手的问题。而这项研究中揭示了大脑中两个完全不同的系统如何共同“合作”导致了成瘾现象。

Worley 此前并不研究药物成瘾问题,他是即时早期基因(immediate early genes)研究方面的专家。即时早期基因是指神经元在接受新信息后很快表达的一类基因。2001 年在一次会议上得知 mGluR 5 缺失导致小鼠对可卡因不“感冒”后, Worley 顿时联想到 mGluR 蛋白可能与即时早期基因有相互作用。

Worley 表示,之前从未想过即时早期蛋白能与多巴胺,成瘾过程产生联系。这恰恰是科学家所钟爱的:“你确信某些事情是这样的,但是你没有证据。”

Worley 领导的研究团队经过了长时间的研究,终于发现了成瘾导致基因改变。并与电生理专家合作,通过多种技术结合的方式,描述出了成瘾过程完整的故事。

Worley 表示,这项研究揭示了可卡因激活学习系统导致成瘾的过程,了解该过程的细节,有助于科学家寻找针对成瘾的有效治疗方法。

Joo Min Park, Jia-Hua Hu, Aleksandr Milshteyn, Ping-Wu Zhang, Chester G. Moore, Sungjin Park, Michael C. Datko, Racquel D. Domingo, Cindy M. Reyes, Xiaodong J. Wang, Felicia A. Etzkorn, Bo Xiao, Karen K. Szumlinski, Dorothee Kern, David J. Linden, Paul F. Worley. A Prolyl-Isomerase Mediates Dopamine-Dependent Plasticity and Cocaine Motor Sensitization. Cell, 1 August 2013; DOI:10.1016/j.cell.2013.07.001

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868666, encodeId=e8f218686669f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 14 21:11:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958902, encodeId=686319589021e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 20 20:11:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481672, encodeId=c8e214816e247, content=<a href='/topic/show?id=7099384244c' target=_blank style='color:#2F92EE;'>#可卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38424, encryptionId=7099384244c, topicName=可卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbbf7815801, createdName=12498b3em10(暂无昵称), createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493786, encodeId=4e521493e8634, content=<a href='/topic/show?id=be6e3842e92' target=_blank style='color:#2F92EE;'>#可卡因成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38427, encryptionId=be6e3842e92, topicName=可卡因成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=360d9095294, createdName=xlysu, createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868666, encodeId=e8f218686669f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 14 21:11:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958902, encodeId=686319589021e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 20 20:11:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481672, encodeId=c8e214816e247, content=<a href='/topic/show?id=7099384244c' target=_blank style='color:#2F92EE;'>#可卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38424, encryptionId=7099384244c, topicName=可卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbbf7815801, createdName=12498b3em10(暂无昵称), createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493786, encodeId=4e521493e8634, content=<a href='/topic/show?id=be6e3842e92' target=_blank style='color:#2F92EE;'>#可卡因成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38427, encryptionId=be6e3842e92, topicName=可卡因成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=360d9095294, createdName=xlysu, createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
    2013-11-20 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868666, encodeId=e8f218686669f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 14 21:11:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958902, encodeId=686319589021e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 20 20:11:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481672, encodeId=c8e214816e247, content=<a href='/topic/show?id=7099384244c' target=_blank style='color:#2F92EE;'>#可卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38424, encryptionId=7099384244c, topicName=可卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbbf7815801, createdName=12498b3em10(暂无昵称), createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493786, encodeId=4e521493e8634, content=<a href='/topic/show?id=be6e3842e92' target=_blank style='color:#2F92EE;'>#可卡因成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38427, encryptionId=be6e3842e92, topicName=可卡因成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=360d9095294, createdName=xlysu, createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868666, encodeId=e8f218686669f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 14 21:11:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958902, encodeId=686319589021e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 20 20:11:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481672, encodeId=c8e214816e247, content=<a href='/topic/show?id=7099384244c' target=_blank style='color:#2F92EE;'>#可卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38424, encryptionId=7099384244c, topicName=可卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbbf7815801, createdName=12498b3em10(暂无昵称), createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493786, encodeId=4e521493e8634, content=<a href='/topic/show?id=be6e3842e92' target=_blank style='color:#2F92EE;'>#可卡因成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38427, encryptionId=be6e3842e92, topicName=可卡因成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=360d9095294, createdName=xlysu, createdTime=Wed Aug 07 04:11:00 CST 2013, time=2013-08-07, status=1, ipAttribution=)]

相关资讯

Sci Transl Med:丁丙诺啡和纳曲酮结合阻止可卡因成瘾

丁丙诺啡(Buprenorphine)是一种可激活μ和κ阿片受体的合成阿片类药物。它可以减少阿片类药物瘾君子可卡因的用量。然而,丁丙诺啡对μ阿片受体强有力的激动剂效应,使得它有可能造成非阿片依赖的可卡因滥用者对阿片的依赖。 研究者假设,结合丁丙诺啡和纳曲酮(naltrexone一种强力μ类阿片拮抗剂,同时具有较弱的δ和κ拮抗剂效果)可以阻止可卡因成瘾,同时避免产生阿片依赖。 研究者利用大鼠,对

BJP:非成瘾水平可卡因摄入可导致认知功能障碍

可卡因成瘾者可表现出持续的认知缺陷,但目前对可卡因娱乐性使用者认知行为的研究十分有限。《英国精神病学杂志》(The British Journal of Psychiatry)7月在线刊登的一篇研究报告显示,娱乐性的和非依赖水平的可卡因使用同样会导致认知缺陷。可卡因的使用和多动障碍(ADHD)间似乎存在认知损害的相互加重作用。 研究为检测相对纯粹的以娱

Baidu
map
Baidu
map
Baidu
map